Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.27
NAS:CYAN's Cash to Debt is ranked lower than
91% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. NAS:CYAN: 0.27 )
Ranked among companies with meaningful Cash to Debt only.
NAS:CYAN' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.63 Max: 8.11
Current: 0.27
0.06
8.11
Equity to Asset 0.56
NAS:CYAN's Equity to Asset is ranked lower than
63% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:CYAN: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
NAS:CYAN' s Equity to Asset Range Over the Past 10 Years
Min: 0.56  Med: 0.76 Max: 0.92
Current: 0.56
0.56
0.92
F-Score: 4
Z-Score: 1.48
M-Score: -4.15
WACC vs ROIC
9.85%
-16.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -2.47
NAS:CYAN's Operating margin (%) is ranked higher than
70% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. NAS:CYAN: -2.47 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:CYAN' s Operating margin (%) Range Over the Past 10 Years
Min: -75.43  Med: 4.13 Max: 11.79
Current: -2.47
-75.43
11.79
Net-margin (%) -14.88
NAS:CYAN's Net-margin (%) is ranked higher than
65% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:CYAN: -14.88 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:CYAN' s Net-margin (%) Range Over the Past 10 Years
Min: -76.68  Med: 4.06 Max: 15.16
Current: -14.88
-76.68
15.16
ROE (%) -25.57
NAS:CYAN's ROE (%) is ranked higher than
56% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. NAS:CYAN: -25.57 )
Ranked among companies with meaningful ROE (%) only.
NAS:CYAN' s ROE (%) Range Over the Past 10 Years
Min: -66.15  Med: 8.02 Max: 27.54
Current: -25.57
-66.15
27.54
ROA (%) -15.08
NAS:CYAN's ROA (%) is ranked higher than
63% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. NAS:CYAN: -15.08 )
Ranked among companies with meaningful ROA (%) only.
NAS:CYAN' s ROA (%) Range Over the Past 10 Years
Min: -54  Med: 5.52 Max: 22.08
Current: -15.08
-54
22.08
ROC (Joel Greenblatt) (%) -3.48
NAS:CYAN's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. NAS:CYAN: -3.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:CYAN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -70.18  Med: 7.63 Max: 32.17
Current: -3.48
-70.18
32.17
Revenue Growth (3Y)(%) 5.50
NAS:CYAN's Revenue Growth (3Y)(%) is ranked higher than
51% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. NAS:CYAN: 5.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:CYAN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.8  Med: 5.5 Max: 18.8
Current: 5.5
-9.8
18.8
EBITDA Growth (3Y)(%) -37.60
NAS:CYAN's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. NAS:CYAN: -37.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:CYAN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -37.6  Med: 11.25 Max: 129.6
Current: -37.6
-37.6
129.6
» NAS:CYAN's 10-Y Financials

Financials (Next Earnings Date: 2017-02-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CYAN Guru Trades in Q4 2015

Jim Simons 91,700 sh (+0.33%)
» More
Q1 2016

CYAN Guru Trades in Q1 2016

Jim Simons 93,500 sh (+1.96%)
» More
Q2 2016

CYAN Guru Trades in Q2 2016

Jim Simons 96,300 sh (+2.99%)
» More
Q3 2016

CYAN Guru Trades in Q3 2016

Jim Simons 97,600 sh (+1.35%)
» More
» Details

Insider Trades

Latest Guru Trades with CYAN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMEX:MSTX, NAS:MRNS, NAS:VKTX, NAS:CLSN, NAS:ABIO, NAS:PRAN, OTCPK:BLEVF, NAS:MBVX, NAS:TKAI, NAS:CSBR, OTCPK:FENCF, NAS:SBOT, AMEX:HEB, OTCPK:ONCYF, NAS:STEM, NAS:CERU, NAS:ORPN, NAS:RTTR, OTCPK:NXTTF, OTCPK:PRGB » details
Cyanotech Corp cultivates and produces natural products derived from microalgae for the nutritional supplements market. The Company's products include Spirulina Pacifica and natural astaxanthin.

Cyanotech Corp was incorporated in 1983. The Company cultivates and produces natural products derived from microalgae for the nutritional supplements market. Its products include Hawaiian Spirulina Pacifica - a nutrient-rich dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits and as a source of antioxidant carotenoids; and Hawaiian BioAstin natural astaxanthin - a powerful dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health. It has expanding applications as a human nutraceutical and functional food ingredient. The Spirulina Pacifica is produced in two forms powder and tablets, and BioAstin is produced in three forms a liquid lipid extract, and gelcaps. Its products are marketed and sold in bulk quantities to manufacturers, formulators and distributors in the health foods and nutritional supplements markets and as packaged consumer products to distributors, retailers and direct consumers. The Company' has four United States patents in force: one on aspects of its production methods and three for use of its BioAstin products. The Company's competitors include Dainippon Ink and Chemical Company's Earthrise facility in California, Parry Nutraceuticals, a division of Murugappa Group of India and several farms in China. Several governmental agencies regulate various aspects of the company's business and its products in the United States, including the Food and Drug Administration, the Federal Trade Commission, the Consumer Product Safety Commission, the State of Hawaii Department of Health, the Department of Agriculture, the Environmental Protection Agency, the United States Postal Service, state attorney general offices and various agencies of the states and localities in which the company's products are sold.

Ratios

vs
industry
vs
history
P/B 1.29
CYAN's P/B is ranked higher than
86% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. CYAN: 1.29 )
Ranked among companies with meaningful P/B only.
CYAN' s P/B Range Over the Past 10 Years
Min: 0.63  Med: 1.39 Max: 3.68
Current: 1.29
0.63
3.68
P/S 0.66
CYAN's P/S is ranked higher than
96% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. CYAN: 0.66 )
Ranked among companies with meaningful P/S only.
CYAN' s P/S Range Over the Past 10 Years
Min: 0.42  Med: 0.96 Max: 2.31
Current: 0.66
0.42
2.31
PFCF 162.08
CYAN's PFCF is ranked lower than
92% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. CYAN: 162.08 )
Ranked among companies with meaningful PFCF only.
CYAN' s PFCF Range Over the Past 10 Years
Min: 5.55  Med: 21.21 Max: 170.83
Current: 162.08
5.55
170.83
POCF 14.54
CYAN's POCF is ranked higher than
60% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. CYAN: 14.54 )
Ranked among companies with meaningful POCF only.
CYAN' s POCF Range Over the Past 10 Years
Min: 4.41  Med: 13.57 Max: 88.24
Current: 14.54
4.41
88.24
EV-to-EBITDA 25.79
CYAN's EV-to-EBITDA is ranked lower than
63% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 16.24 vs. CYAN: 25.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYAN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -102.1  Med: 10 Max: 98.8
Current: 25.79
-102.1
98.8
Current Ratio 1.93
CYAN's Current Ratio is ranked lower than
76% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CYAN: 1.93 )
Ranked among companies with meaningful Current Ratio only.
CYAN' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 3.11 Max: 7.93
Current: 1.93
1.13
7.93
Quick Ratio 0.85
CYAN's Quick Ratio is ranked lower than
87% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. CYAN: 0.85 )
Ranked among companies with meaningful Quick Ratio only.
CYAN' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.74 Max: 7.07
Current: 0.85
0.54
7.07
Days Inventory 133.43
CYAN's Days Inventory is ranked lower than
51% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. CYAN: 133.43 )
Ranked among companies with meaningful Days Inventory only.
CYAN' s Days Inventory Range Over the Past 10 Years
Min: 70.29  Med: 99.59 Max: 141.39
Current: 133.43
70.29
141.39
Days Sales Outstanding 33.86
CYAN's Days Sales Outstanding is ranked higher than
73% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. CYAN: 33.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYAN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.78  Med: 47.28 Max: 62.12
Current: 33.86
30.78
62.12
Days Payable 74.99
CYAN's Days Payable is ranked higher than
60% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. CYAN: 74.99 )
Ranked among companies with meaningful Days Payable only.
CYAN' s Days Payable Range Over the Past 10 Years
Min: 26.29  Med: 43.7 Max: 74.99
Current: 74.99
26.29
74.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.80
CYAN's 3-Year Average Share Buyback Ratio is ranked higher than
89% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. CYAN: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYAN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.9  Med: -1.2 Max: -0.1
Current: -0.8
-7.9
-0.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.28
CYAN's Price/Tangible Book is ranked higher than
89% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CYAN: 1.28 )
Ranked among companies with meaningful Price/Tangible Book only.
CYAN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.5  Med: 1.38 Max: 3.71
Current: 1.28
0.5
3.71
Price/Projected FCF 5.20
CYAN's Price/Projected FCF is ranked lower than
65% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. CYAN: 5.20 )
Ranked among companies with meaningful Price/Projected FCF only.
CYAN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.84 Max: 15.09
Current: 5.2
0.75
15.09
Price/Median PS Value 0.70
CYAN's Price/Median PS Value is ranked higher than
69% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CYAN: 0.70 )
Ranked among companies with meaningful Price/Median PS Value only.
CYAN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.47  Med: 1.34 Max: 10.06
Current: 0.7
0.47
10.06
Earnings Yield (Greenblatt) (%) -2.98
CYAN's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. CYAN: -2.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CYAN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3.17  Med: 7.65 Max: 18.2
Current: -2.98
-3.17
18.2
Forward Rate of Return (Yacktman) (%) 3.55
CYAN's Forward Rate of Return (Yacktman) (%) is ranked lower than
72% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.80 vs. CYAN: 3.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CYAN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -3  Med: 1.3 Max: 37.2
Current: 3.55
-3
37.2

More Statistics

Revenue (TTM) (Mil) $32.91
EPS (TTM) $ -0.87
Beta1.38
Short Percentage of Float0.44%
52-Week Range $3.32 - 5.80
Shares Outstanding (Mil)5.67
» More Articles for CYAN

Headlines

Articles On GuruFocus.com
Cyanotech Corp. Reports Operating Results (10-Q) Feb 11 2011 
Cyanotech Corp. Reports Operating Results (10-Q) Nov 10 2010 
Cyanotech Corp. Reports Operating Results (10-K) Jun 24 2010 
Cyanotech Corp. Reports Operating Results (10-Q) Feb 11 2010 
Cyanotech Corp. Reports Operating Results (10-Q) Nov 12 2009 
Cyanotech Corp. Reports Operating Results (10-Q) Aug 13 2009 
Cyanotech Corp. Reports Operating Results (10-Q) Feb 13 2009 

More From Other Websites
CYANOTECH CORP Financials Nov 18 2016
Kailua-Kona-based Cyanotech reports second-quarter financials Nov 11 2016
Cyanotech Corp. :CYAN-US: Earnings Analysis: Q2, 2017 By the Numbers : November 11, 2016 Nov 11 2016
Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal Year 2017 Nov 10 2016
CYANOTECH CORP Files SEC form 10-Q, Quarterly Report Nov 10 2016
Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal Year 2017 Nov 10 2016
Cyanotech Names Nancy Katz as a Director Oct 25 2016
CYANOTECH CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Oct 25 2016
Cyanotech Names Nancy Katz as a Director Oct 25 2016
Cyanotech® Corporation Earns Non-GMO Project Verification for BULK SCE BioAstin® Natural... Sep 22 2016
CYANOTECH CORP Files SEC form 8-K, Other Events Sep 09 2016
CYANOTECH CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... Sep 01 2016
CYANOTECH CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Aug 29 2016
CYANOTECH CORP Files SEC form 10-Q, Quarterly Report Aug 15 2016
Cyanotech Reports Financial Results for the First Quarter of Fiscal Year 2017 Aug 15 2016
Cyanotech Reports Financial Results for the First Quarter of Fiscal Year 2017 Aug 15 2016
Cyanotech Corp. :CYAN-US: Earnings Analysis: 2016 By the Numbers : July 26, 2016 Jul 26 2016
Cyanotech Corp. :CYAN-US: Earnings Analysis: Q4, 2016 By the Numbers : June 30, 2016 Jun 30 2016
CYANOTECH CORP Files SEC form 10-K, Annual Report Jun 23 2016
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2016 Jun 23 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)